LOS ANGELES, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Roche Holding
AG (“Roche” or the “Company”) (Other OTC:RHHBY) for possible violations of federal securities laws from March 2, 2017 through June
5, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Roche shares during the Class Period should
contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by
an attorney. You may choose to do nothing and be an absent class member as well.
The lawsuit alleges that throughout the Class Period, Roche issued materially false and misleading statements, and/or failed to
disclose, that the combination of its breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more
successful than Herceptin alone in preventing breast cancer; and that as a result, Roche’s statements about its business,
operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When this
news was announced, Roche’s stock price fell materially, causing investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’
rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of
ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 brian@lundinlawpc.com http://lundinlawpc.com/
